

Expert	Type of Relationship with Industry	
Ahrens Ingo	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen, Astra Zeneca, Boehringer-Ingelheim, Daiichi Sankyo, Bayer Healthcare</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Acuet CardioVascular Care Association /ESC Working group on Cardiovascular Emergency- and Intensive Care medicine (AG3) /German Cardiac Society</p>
	2025	<p>Payment from healthcare industry Daiichi Sankyo, Bayer Healthcare, Penumbra</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings, unrelated to any specific activity Lilly</p> <p>Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions: German Cardiac Society Vice Chair working group on Cardiac Intensive and Emergency Medicine</p>
Aleksic Milica	2024	Nothing to be declared
	2025	Nothing to be declared
Arrigo Mattia	2024	Nothing to be declared
	2025	Nothing to be declared
Baneras Rius Jordi	2024	Nothing to be declared
	2025	<p>Payment from healthcare industry Johnson & Johnson</p>
Chacon-Lozsan Francisco Jose	2024	Nothing to be declared
	2025	Nothing to be declared
Combes Alain	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Baxter, Maquet</p>
	2025	<p>Payment from healthcare industry Baxter, Maquet</p>

Expert	Type of Relationship with Industry	
Gevaert Sofie	2024	Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim
	2025	Payment from healthcare industry to department or institution or any other body for personal services Daiichi Sankyo
Grand Johannes	2024	Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity The Alfred Benzon Foundation □ C/O Rigshospitalet – Copenhagen University Hospital
	2025	Ongoing research funding from public and/or not-for-profit organisations The Alfred Benzon Foundation □ C/O Rigshospitalet – Copenhagen University Hospital
Halvorsen Sigrun	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Novartis, Pfizer, Sanofi Aventis, Bristol Myers Squibb, Novo-Nordisk, Boehringer Ingelheim
	2025	Payment from healthcare industry Sanofi Aventis Payment from healthcare industry to department or institution or any other body for personal services Boehringer-Ingelheim, Bristol Myers Squibb, Novo Nordisk, Pharmacosmos
Huber Kurt	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen, Boehringer-Ingelheim, Daiichi Sankyo, Novartis, Sanofi Aventis, Chiesi Pharma, Astrazeneca
	2025	Payment from healthcare industry Amgen, Boehringer-Ingelheim, Daiichi Sankyo, Novartis, Sanofi Aventis, Chiesi Pharma, Astrazeneca Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions: Austrian Heart Foundation Medical Private University Burgenland Positions as Editor in Chief: Austrian Journal of Cardiology (J Kardiol) Other editorial positions: None
Jorge Perez Pablo	2024	Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Becton Dickinson
	2025	Nothing to be declared

Expert	Type of Relationship with Industry
Klok Erik	<p>2024 Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one’s ability to join an ESC activity The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Foundation, The Dutch Heart Foundation and the Horizon Europe Program Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boston Scientific Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). Senior Editor Thrombosis Research Chair of Dutch Thrombosis Network Chair of Dutch association of vascular medicine Medical lead Anticoagulation clinic Leiden (as part of my clinical staff position in Leiden)</p> <hr style="border-top: 1px dashed black;"/> <p>2025 Ongoing research funding from public and/or not-for-profit organisations The Netherlands Organisation for Health Research and Development, The Dutch Thrombosis Foundation, The Dutch Heart Foundation and the Horizon Europe Program Payment from healthcare industry to department or institution or any other body for personal services Boston Scientific, Angiodynamics Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions:Chair of Dutch Society of Vascular Medicine Positions as Editor in Chief:N.A. Other editorial positions:Senior Editor Thrombosis Research Editorial board member JTH and RPTH</p>
Krychtiuk Konstantin A	<p>2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Amgen, Daiichi Sankyo, Novartis, Sanofi Aventis, Zoll Medical, Amarin Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Amgen, Daiichi Sankyo Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. ACC HeartPAC 2022 attendee</p>

Expert	Type of Relationship with Industry
Krychtiuk Konstantin A	<p>2025</p> <p>Payment from healthcare industry Daiichi Sankyo, Novartis, Amgen Inc, Amarin</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings, unrelated to any specific activity Daiichi Sankyo, Amgen Inc</p> <p>Research funding from healthcare industry received by department/institution or an entity controlled by department/institution, under direct/personal responsibility Eli Lilly, Novartis, Amgen Inc</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine/sciences Board Member ESC Association for Acute CardioVascular Care</p>
Leonardi Sergio	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Bristol Myers Squibb, Novo-Nordisk</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Astra Zeneca</p> <hr/> <p>2025</p> <p>Payment from healthcare industry Astra Zeneca, Bristol Myers Squibb, Novo-Nordisk</p> <p>Research funding from healthcare industry received by department/institution or an entity controlled by department/institution, under direct/personal responsibility Astra Zeneca</p>
Mills Nicholas	<p>2024</p> <p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity British Heart Foundation Fellowships (FS/IBSRF/23/25161, FS/CRTF/23/24491)</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position (e.g. editorial role in non-ESC publications—editor in chief or other editorial position—and/or officer position in other organisations). I am an Associate Editor at the American Heart Association journal Circulation for which I receive modest remuneration for my time commitment (<10k per annum)</p> <hr/> <p>2025</p> <p>Ongoing research funding from public and/or not-for-profit organisations British Heart Foundation Chair Award (CH/F/21/90010), Research Excellence Award (RE/24/130012), and Programme Grant (RG/F/25/110169)</p>
Poess Janine	<p>2024</p> <p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Overcome</p>

Expert	Type of Relationship with Industry	
Poess Janine	2025	<p>Payment from healthcare industry Overcome GmbH</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine/sciences only within ESC and German Cardiac Society</p> <p>Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions:Active member of German National Cardiac Society Positions as Editor in Chief:none Other editorial positions:none</p>
Schaubroeck Hannah	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Belgian Interdisciplinary Working group of Acute Cardiology (BIWAC)</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abiomed</p> <p>Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. GETINGE</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine. Board member (and past president) of Belgian Interdisciplinary working group of acute cardiology (BIWAC) - daughter organisation of BSC (Belgian society of Cardiology) BSC member (Belgian society of Cardiology) ESICEM member (European society of Intensive Care Medicine)</p>
	2025	<p>Ongoing research funding from public and/or not-for-profit organisations Belgian Interdisciplinary Working group of Acute Cardiology (BIWAC)</p> <p>Payment from healthcare industry to department or institution or any other body for personal services Boehringer-Ingelheim</p> <p>Research funding from healthcare industry received by department/institution or an entity controlled by department/institution, under direct/personal responsibility Belgian Interdisciplinary Working group of Cardiology</p>

Expert	Type of Relationship with Industry	
Schaubroeck Hannah	2025	<p>Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions:Belgian Interdisciplinary Working group of Cardiology (BIWAC, part of Belgian Society of Cardiology) - board member</p>
Schrage Benedikt	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed, Astrazeneca, INARI Research funding from healthcare industry received by your department/institution or an entity controlled by your department/institution , under your direct/personal responsibility. Abiomed</p>
	2025	<p>Payment from healthcare industry Abiomed, Astrazeneca, INARI Research funding from healthcare industry received by department/institution or an entity controlled by department/institution, under direct/personal responsibility Novo-Nordisk, Abiomed</p>
Sionis Alessandro	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Instituto de Salud Carlos III Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Daiichi Sankyo, Sanofi Aventis Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Daiichi Sankyo</p>
	2025	<p>Ongoing research funding from public and/or not-for-profit organisations CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED Enfermedades Cardiovasculares, Hospital de la Santa Creu i Sant Pau Payment from healthcare industry Daiichi Sankyo, Sanofi Aventis Funding from healthcare industry for travel to, and attendance of events and meetings, unrelated to any specific activity Amgen</p>
Stratinaki Maria	2024	Nothing to be declared
	2025	Nothing to be declared
Tavazzi Guido	2024	Nothing to be declared

Expert	Type of Relationship with Industry	
Tavazzi Guido	2025	Nothing to be declared
Tycinska Agnieszka	2024	<p>Ongoing research funding from public and/or not-for-profit organisations. This information is not mandatory and does not impact one's ability to join an ESC activity Polish Research Agency Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Bayer, Boehringer-Ingelheim, Pfizer, Servier Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Servier</p>
	2025	<p>Ongoing research funding from public and/or not-for-profit organisations Polish Research Agency Payment from healthcare industry Servier Funding from healthcare industry for travel to, and attendance of events and meetings, unrelated to any specific activity Servier</p>
Vandenbriele Christophe	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abiomed Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Abiomed</p>
	2025	<p>Payment from healthcare industry Abiomed</p>
Verbrugge Frederik Hendrik	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Abbott, Astra Zeneca, Edwards Lifesciences, Biotronik, Menarini, Bayer Healthcare, Novo-Nordisk Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Boehringer-Ingelheim Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Johnson & Johnson</p>

Expert	Type of Relationship with Industry
Verbrugge Frederik Hendrik	<p>2024 Direct financial interest in healthcare, media, education companies, or in companies related to or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. Healthcare - Device Therapy, Risk Factors and Prevention - Modest stock positions in Eli Lilly and Boston Scientific (<20K€)</p>
	<p>2025 Payment from healthcare industry Abbott, Astra Zeneca, Boehringer-Ingelheim, Edwards Lifesciences, Eli Lilly, Novartis, Menarini, Europa, Novo-Nordisk, Roche Diagnostics, Abiomed Europe GmbH</p> <p>Payment from healthcare industry to department or institution or any other body for personal services Boehringer-Ingelheim</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings, unrelated to any specific activity Astra Zeneca, Johnson & Johnson, Bayer Healthcare</p> <p>Research funding from healthcare industry received by department/institution or an entity controlled by department/institution, under direct/personal responsibility Roche Diagnostics</p> <p>Direct financial interest in healthcare, media, education companies or in companies related to or in competition with the ESC and its mission Healthcare - Chronic Heart Failure - Limited stock position (<10K) in Eli Lilly, Novartis and Boston Scientific as personal investment.</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiovascular medicine/sciences - Deputy Editor for European Heart Journal: Acute Cardiovascular Care - Board member and co-chair of the Research Committee for the Acute Cardiovascular Care association (ACVC) of the European Society of Cardiology - Member of the ACVC Study Group on Acute Heart Failure - Member of the HFA Scientific Committee on HFmrEF & HFpEF - HFA Certification Task Force member</p> <p>Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Leadership positions:Co-chair Therapy Adoption of the PCR Mitral Focus Group Positions as Editor in Chief:N/A Other editorial positions:Editorial Consultant for JACC: Heart Failure</p>
Vidal-Perez Rafael Carlos	<p>2024 Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. Astra Zeneca, Daiichi Sankyo, Bristol Myers Squibb, Organon</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings , unrelated to the activities listed in 2.A and 3.A. Bayer, Daiichi Sankyo, Novartis, Rovi</p>

Expert	Type of Relationship with Industry	
Vidal-Perez Rafael Carlos	2025	<p>Payment from healthcare industry Daiichi Sankyo, Esteve</p> <p>Funding from healthcare industry for travel to, and attendance of events and meetings, unrelated to any specific activity Bayer, Daiichi Sankyo, Rovi</p> <p>Positions of influence in non-ESC organisations and non-ESC journals with a focus in the field of cardiovascular medicine/sciences Other editorial positions: World Journal of Cardiology (editorial board)</p>
Vranckx Pascal	2024	<p>Payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities. CSL Behring, Janssen-Bristol Myers Squibb alliance</p>
	2025	Nothing to be declared